Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials

BMC Cardiovascular Disorders

Meng-Hua Chen¹  Tao Qin¹  Pravesh Kumar Bundhun¹ 

[1] Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning 530027, Guangxi, P. R. China

关键词: Coronary stents implantation;    Type 2 diabetes mellitus;    Cilostazol;    Antiplatelet therapy;   

Others  :  1229138
DOI  :  10.1186/s12872-015-0114-1

 received in 2015-06-26, accepted in 2015-09-25,  发布年份 2015

【 摘 要 】

Background

Since antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients is very important after intracoronary stenting, and because the most commonly used therapies have been the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel and the triple antiplatelet therapy (TAPT) consisting of aspirin, clopidogrel and cilostazol, we aim to compare the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in T2DM patients.

Methods

Systematic literature search was done from the databases of PubMed, Cochrane, Embase, China National Knowledge Infrastructure (CNKI) and WanFang. Randomized controlled trials (RCTs) comparing the effectiveness and safety between triple therapy and dual therapy in T2DM patients after coronary stents placement were included. Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9–12 months period, as well as platelet activities.

Results

Four studies including 1005 patients reporting the adverse clinical outcomes and six studies including 519 patients reporting the platelet activities, with a total of 1524 patients have been analyzed in this meta-analysis. The pooling analysis shows that TAPT has significantly decreased the occurrence of MACEs (RR: 0.55; 95 % CI: 0.36–0.86, P = 0.009), TLR (RR 0.41; 95 % CI: 0.21–0.80, P = 0.008), TVR (RR 0.55; 95 % CI: 0.34–0.88, P = 0.01) and the overall incidence of Death/ Myocardial Infarction (MI)/TVR (RR 0.54; 95 % CI: 0.31–0.94, P = 0.03) during this 9 to 12 months follow up period after stents implantation. Stent thrombosis was almost similar in both groups. Bleeding seemed to favor DAPT but the result was not statistically significant. Platelet aggregation, platelet reactivity index (PRI) and platelet reactivity unit (PRU) were also reduced with Weight Mean Difference (WMD) of (−13.80; 95 % CI: −17.03 to −10.56, P < 0.00001), (−22.87; 95 % CI: −23.66 to −22.07, P < 0.00001) and (−44.17; 95 % CI: −58.56 to −29.77, P < 0.00001) respectively.

Conclusion

Since MACEs have been significantly decreased in the triple group, TAPT appears to be more effective than DAPT in T2DM patients after intracoronary stenting. No significant difference in stent thrombosis and bleeding risks between these 2 groups shows TAPT to be almost as safe as DAPT in these diabetic patients.

【 授权许可】

   
2015 Bundhun et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, et al.: Impact of diabetes on long-term outcome after primary Angioplasty: insights from the DESERT cooperation. Diabetes Care 2013, 36(4):1020-5.
• [2]Colwell JA, Nesto RW: The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003, 26:2181-8.
• [3]Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al.: Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007, 30:372-4.
• [4]Brilakis ES, Patel VG, Banerjee S: Medical management after coronary stent implantation: a review. JAMA 2013, 310(2):189-98.
• [5]Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al.: Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008, 51:1181-7.
• [6]Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, et al.: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary interve ntion in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009, 157(4):733-9.
• [7]Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH: CLASSICS Investigators: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000, 102:624-9.
• [8]Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-57.
• [9]Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
• [10]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430–5.
• [11]Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
• [12]Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103:11069–74.
• [13]Sumpio BE, Aruny J: Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Perspect Vasc Surg Endovasc Ther 2005, 17:265-7.
• [14]Angiolillo DJ: Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009, 32(4):531-40.
• [15]Mohammad RA, Goldberg T, Dorsch MP, Cheng JW: Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. Clin Ther 2010, 32(14):2265-81.
• [16]Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014;1(1), e000068.
• [17]Min P-K, Jung J, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting. Circ J. 2007;71:1685–90.
• [18]Lee S-W, Park S, Yun S, Kim YH, Park DW, Kim WJ, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-eluting stenting followed by cilostazol treatment reduces adverse serious cardiac events (DECREASE registry). Am Heart J. 2010;284–91.
• [19]Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;167:2250–8.
• [20]Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv. 2011;4:381–91.
• [21]Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al.: Coronary stent restenosis in patients treated with cilostazol. Circulation 2005, 112(18):2826-32.
• [22]Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, et al.: Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance doseclopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus highmaintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010, 3(1):17-26.
• [23]Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, et al.: Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008, 72(1):35-9.
• [24]Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease results of the CILON-T (Influence of CILostazolbased triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial. J Am Coll Cardiol. 2011;57:280–9.
• [25]Doo-Soo Jeon MD, Yoo K-D, Park CS, Shin DI, Her SH, et al. The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J. 2010;40(1):10–5.
• [26]Rogers KC, Faircloth JM, Finks SW: Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother 2012, 46:839-50.
• [27]Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359(9302):189-98.
• [28]Geeganage C, Wilcox R, Bath PMW: Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med 2010, 8:36. BioMed Central Full Text
• [29]Pratt CM: Analysis of the cilostazol safety database. Am J Cardiol 2001, 87(12A):28D-33.
• [30]Rendell M, Cariski AT, Hittel N, Zhang P: Cilostazol treatment of claudication in diabetic patients. Curr Med Res Opin 2002, 18(8):479-87.
• [31]Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al.: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010, 9(10):959-68.
• [32]Kanlop N, Chattipakorn S, Chattipakorn N: Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown) 2011, 12(2):88-95.
• [33]Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al.: A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelettherapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011, 57(11):1264-70.
• [34]Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al.: Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007, 100(7):1103-8.
• [35]Yang TH, Kim DI, Kim DK, Jang JS, Kim U, Seol SH, et al.: Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med 2011, 26(2):145-52.
• [36]Yang TH, Kim DI, Kim JY, Kim IH, Kim KH, Han YC, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J. 2009;39(11):462–6.
• [37]Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, et al.: Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheter Cardiovasc Interv 2013, 81(1):42-9.
• [38]Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29:2202–11.
• [39]Angiolillo DJ, Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, et al.: Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011, 106(2):253-62.
• [40]Ha SJ, Kim SJ, Hwang SJ, Woo JS, Kim W, Kim WS, et al.: Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. Coron Artery Dis 2013, 24(8):690-7.